Hikma Pharmaceuticals: all 118 studies

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy PatientsNot yet recruitingNCT07891780Phase 2
• Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid LeukemiaRecruitingNCT05282108
• Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IVRecruitingNCT02323399Phase 4
• Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric SubjectsCompletedNCT01322360Phase 4Results posted
• Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted ConditionsCompletedNCT01107353Not applicableResults posted
• Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) PatientsActive, not recruitingNCT06572982Not applicable
• Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)CompletedNCT06326697Phase 1
• Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With SchizophreniaCompletedNCT05563818
• Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in EgyptCompletedNCT05423769
• Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA RegionCompletedNCT04468165
• Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
• Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)CompletedNCT03535870Not applicable
• Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in JordanCompletedNCT03517982
• Efficacy and Safety of a Generic Rosuvastatin in a Real-world SettingCompletedNCT03516955
• Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.TerminatedNCT03460678Phase 4
• Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in EgyptCompletedNCT03454503
• Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia PatientsCompletedNCT03452501
• Study of Oral Morphine Sulfate Administration in Pediatric SubjectsCompletedNCT03429400Phase 3
• Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in JordanCompletedNCT03348046
• Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in JordanCompletedNCT02977312
• Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol XinafoateCompletedNCT02649478Not applicable
• Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted ConditionsCompletedNCT01903122Early Phase 1
• Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed ConditionsCompletedNCT01903109Early Phase 1
• Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted ConditionsCompletedNCT01712139Not applicable
• Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed ConditionsCompletedNCT01712126Not applicable
• Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted ConditionsCompletedNCT01712113Not applicable
• Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed ConditionsCompletedNCT01712100Not applicable
• Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed ConditionsCompletedNCT01703468Phase 1
• Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted ConditionsCompletedNCT01702623Phase 1
• A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural PainTerminatedNCT01676493Phase 3
• Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted ConditionsCompletedNCT01659931Early Phase 1
• Bioequivalency Study of Montelukast 10 mg Tablets Under Fed ConditionsCompletedNCT01659918Early Phase 1
• Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted ConditionsCompletedNCT01659905Early Phase 1
• Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed ConditionsCompletedNCT01659892Early Phase 1
• Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed ConditionsCompletedNCT01591889Phase 1
• Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted ConditionsCompletedNCT01570959Not applicable
• Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted ConditionsCompletedNCT01570907Not applicable
• Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed ConditionsCompletedNCT01570894Not applicable
• Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted ConditionsCompletedNCT01367652Phase 1
• Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed ConditionsCompletedNCT01367626Phase 1
• Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNCT01331447Not applicable
• Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsCompletedNCT01331434Not applicable
• Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNCT01331421Not applicable
• Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted ConditionsCompletedNCT01321515Not applicable
• Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed ConditionsCompletedNCT01321502Not applicable
• Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset SeizuresCompletedNCT01284556Phase 3
• Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed ConditionsCompletedNCT01216878Not applicable
• Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted ConditionsCompletedNCT01216852Not applicable
• Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted ConditionsCompletedNCT01210638Phase 1
• Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted ConditionsCompletedNCT01161667Not applicable
• Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed ConditionsCompletedNCT01161654Not applicable
• Bioequivalency Study of Anastrozole 1 mg Under Fasted ConditionsCompletedNCT01155102Not applicable
• Bioequivalency Study of Anastrozole 1 mg Under Fed ConditionsCompletedNCT01155089Not applicable
• Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting ConditionsCompletedNCT01132729Not applicable
• Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed ConditionsCompletedNCT01132716Not applicable
• Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted ConditionsCompletedNCT01102478Not applicable
• Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed ConditionsCompletedNCT01102465Not applicable
• Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed ConditionsCompletedNCT01013155Not applicable
• Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted ConditionsCompletedNCT01012687Not applicable
• Comparative Bioavailability Study of Codeine SulfateCompletedNCT01010152Phase 1
• Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted ConditionsCompletedNCT01010139Not applicable
• Food Effect Study of Codeine SulfateCompletedNCT01009892Phase 1
• Steady State Study of Codeine SulfateCompletedNCT01009853Phase 1
• Dose Linearity Study of Codeine Sulfate Under Fasted ConditionsCompletedNCT01009697Phase 1
• Bioequivalency Study of Morphine Sulfate Injection, Solution and Tablet Under Fasted ConditionsCompletedNCT00994942Not applicable
• Dose Proportionality and Food Effect of Morphine SulfateCompletedNCT00994539Not applicable
• Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled ReleaseCompletedNCT00994383Not applicable
• Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted ConditionsCompletedNCT00992095Not applicable
• Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted ConditionsCompletedNCT00894088Not applicable
• Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed ConditionsCompletedNCT00893958Not applicable
• Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed ConditionsCompletedNCT00893919Not applicable
• Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted ConditionsCompletedNCT00893542Not applicable
• Bioequivalency Study of Levetiracetam 1g Tablets Under Fed ConditionsCompletedNCT00827320Not applicable
• Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting ConditionsCompletedNCT00826865Not applicable
• Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed ConditionsCompletedNCT00826787Not applicable
• Bioequivalency Study of Levetiracetam 1g Under Fasted ConditionsCompletedNCT00826722Not applicable
• Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted ConditionsCompletedNCT00754962Not applicable
• Bioequivalency Study of Ramipril 10 mg Capsules Under Fed ConditionsCompletedNCT00702260Not applicable
• Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting ConditionsCompletedNCT00702091Not applicable
• Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed ConditionsCompletedNCT00694317Not applicable
• Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting ConditionsCompletedNCT00694187Not applicable
• A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsCompletedNCT00674310Not applicable
• A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsCompletedNCT00673088Not applicable
• A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting ConditionsCompletedNCT00618254Not applicable
• Bioequivalency Study of Balsalazide Capsules Under Fasting ConditionsCompletedNCT00618228Not applicable
• A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting ConditionsCompletedNCT00618202Not applicable
• Bioequivalency Study of Meloxicam Tablets Under Fasting ConditionsCompletedNCT00618163Not applicable
• A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed ConditionsCompletedNCT00618111Not applicable
• Bioequivalency Study of 7.5 mg Pilocarpine Under Fed ConditionsCompletedNCT00618059Not applicable
• Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed ConditionsCompletedNCT00618046Not applicable
• Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed ConditionsCompletedNCT00616863Not applicable
• Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting ConditionsCompletedNCT00616681Not applicable
• Bioequivalency Study of Sertraline Under Fasting ConditionsCompletedNCT00602849Not applicable
• Bioequivalency Study of Zolpidem Tartrate Under Fed ConditionsCompletedNCT00602719Not applicable
• Bioequivalency Study of Torsemide Tablets Under Fed ConditionsCompletedNCT00602615Not applicable
• Bioequivalency Study of Zidovudine Under Fasting ConditionsCompletedNCT00602550Not applicable
• Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting ConditionsCompletedNCT00602524Not applicable
• Bioequivalency Study of Clarithromycin Tablets Under Fed ConditionsCompletedNCT00602498Not applicable
• Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting ConditionsCompletedNCT00602407Not applicable
• Bioequivalency Study of 300 mg Lithium Carbonate Under Fed ConditionsCompletedNCT00602394Not applicable

← Hikma Pharmaceuticals overview and focus areas